MedTrace Logo

A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

NCT01878201 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2014-09-08

No results posted yet for this study

Summary

The purpose of this study is to Evaluate the Antihypertensive efficacy of Fimasartan 30 mg during 24 hours in Patients with Mild to Moderate Essential Hypertension

Conditions

  • Essential Hypertension

Interventions

DRUG

Fimasartan

Fimasartan 30 mg

DRUG

Valsartan

Valsartan 80 mg

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Asan Medical Center

    collaborator OTHER

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Kyungpook National University Hospital

    collaborator OTHER

  • Chonnam National University Hospital

    collaborator OTHER

  • Inje University

    collaborator OTHER

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Byung-He Oh, professor · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01878201 on ClinicalTrials.gov